Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of VNA-318 in Healthy Male Subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Dec 2024 According to a Vandria media release, company has closed a $32M Series A to fund this Phase 1 trial, its analysis, and to plan for the efficacy-focused Phase 1b / 2a trials of VNA-318 with the first expected to commence in Q1 2026 or earlier.
18 Dec 2024 According to a Vandria media release, first subjects have been dosed in this study. and readout from this trial is expected in the summer of 2025.
21 Aug 2024 According to a Vandria media release, the company received $30.7M (CHF28.3M) series A financing proceeds will be used for completion of this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com